RXi Pharmaceuticals, a clinical-stage drug company based in Marlborough, on Monday announced positive results from a clinical trial of its lead drug candidate, RXI-109, a compound designed to reduce hypertrophic scarring after surgery and traumatic injury.
According to a company statement, scars treated in the Phase 2 clinical trial showed statistically-significant improvement in appearance following scar revision surgery, and treatment with RXI-109, and the treatment was shown to be safe and well tolerated. In addition, cosmetic outcomes of RXI-109 treated scars were highly preferred over the untreated revised scars, by both investigators and patients, according to RXi.
According to the company, there is a high, unmet need for treatments to reduce scarring after surgery, with a market potential as high as $1.5 billion. Currently, cosmetic therapies such as Botox are used to reduce the appearance of scars, but there is no approved treatment to prevent hypertrophic scarring.
